MarketPeel
Insider Trading Intelligence
LB

Linda Burkly

EDIT
EVP, CHIEF SCIENTIFIC OFFICER · EDITAS MEDICINE, INC. · CIK 0001985604
FILING MIX · LIFETIME50%/50%
BUYS
8
SELLS
8
TOTAL VALUE
$90.2K
COMPANIES
1
ACTIVE SINCE
Jul 2023
HOLDINGS NOW
67,297
AVG SELL PX
$3.83
TRADE KIND
SHOWING 16 / 16
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 12 pending
Forward-return performance of every backtestable P/S trade by Linda Burkly, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+42.86%+4.59%-0.03%+4.62%+1.08%
14d7+28.57%+2.19%-0.39%+2.58%+6.40%
30d7+42.86%+7.30%+0.70%+6.59%+0.34%
60d7+42.86%+11.82%+3.96%+7.86%+16.25%
90d7+42.86%+7.90%+5.38%-7.76%-7.86%
180d7(1 pending)+50.00%+0.74%+11.13%-19.50%-20.62%
1y7(4 pending)+33.33%+11.98%+19.29%-28.80%-28.80%
2y7(7 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
EDIT · 67,297 shares · as of Jun 3, 2026
073,214146,428219,642292,856202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 8 buys / 8 sellsCOVERAGE · 12 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
731$2.70$2.0K67,297Jun 3, 2026Jun 5, 2026View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
292,856292,856Mar 12, 2026Mar 16, 2026View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
749$2.02$1.5K68,028Mar 3, 2026Mar 4, 2026View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
713$2.15$1.5K68,777Dec 3, 2025Dec 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
710$2.60$1.8K69,490Sep 3, 2025Sep 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
5,121$2.49$12.8K64,398Jul 31, 2025Aug 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
726$1.72$1.3K69,519Jun 3, 2025Jun 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
70,00070,000Mar 8, 2025Mar 27, 2025View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
275,100275,100Mar 8, 2025Mar 27, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
2,891$1.71$4.9K70,245Mar 4, 2025Mar 5, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
11,886$5.42$64.4K73,136Jul 25, 2024Jul 26, 2024View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
74,40074,400Mar 2, 2024Mar 5, 2024View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
24,80069,967Mar 2, 2024Mar 5, 2024View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
15,05585,022Mar 2, 2024Mar 5, 2024View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
135,500135,500Jul 24, 2023Jul 25, 2023View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
45,16745,167Jul 24, 2023Jul 25, 2023View →
Other insiders · EDIT
Loading peer insiders…
About this filer
CIK 0001985604
ROLE
EVP, CHIEF SCIENTIFIC OFFICER
PRIMARY
EDIT
COMPANIES
1
ACTIVE SINCE
Jul 2023
MARKETPEEL · /INSIDER/0001985604DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback